This ADC product is comprised of an anti-TMEFF2 monoclonal antibody conjugated via a VC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE
* VAT and and shipping costs not included. Errors and price changes excepted